Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Pasithea Therapeutics Corp

KTTA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.51

▲ +3.41%

Market Cap $16.93M · Vol 87.64K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$16.93M

Micro Cap

Div Yield

N/A

EPS Growth

+73.79%

YoY

RSI (14)

37.62

Momentum

Beta

0.30

vs Market

52W High

$2.06

76.21% below

52W Low

$0.29

71.81% above

Volume

87.64K

Avg 31.15K

P/B

0.54

Price-to-book

ROE

N/A

Return on equity

Free Float

98.89%

Public shares

Shariah Compliance8 STANDARDS

✗ Pasithea Therapeutics Corp (KTTA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KTTA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.17%

+6.00%

+0.88%

-40.74%

YTD

-60.72%

-29.64%

-94.93%

-99.20%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-20,427,680.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-53.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.54
P/FCF	N/A
EPS Growth	+73.79%
Outstanding Shares	33.41M

Technical Indicators

50-Day SMA	$0.50
200-Day SMA	$0.73
RSI (14)	37.62
Beta	0.30
52-Week High	$2.06
52-Week Low	$0.29

Volume Today	87.64K
Avg Daily Volume (30D)	31.15K
Relative Volume	2.81x
Volatility (10D)	45.65
Volatility (30D)	78.60
Free Float	98.89%

Analyst Consensus

BUY

Current Price $0.51

Mean Target $3.00

52W Low$0.29 52W High$2.06

Current

Target

$0.29 $2.06

Current Analyst target

+492.07% upside potential · 1 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01018ZHS3

ISINUS70261F2020

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.